About: SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects
Creator	Mathieu, Chantal Caerels, Simon Janssens, Birgit
Source	Medline; PMC
abstract	Even before sodium-glucose cotransporter inhibitors (SGLTi) became popular agents for the treatment of people with type 2 diabetes (T2DM), clinicians had explored their potential as adjunct therapies in type 1 diabetes (T1DM). Several trials have demonstrated improved glycemic control (compared with placebo) and a decrease in glucose variability with a clinically relevant increase of time in range. In addition, weight loss and decreased systolic blood pressure are observed. The magnitude of the effects observed depends on the type of SGLTi, the dose administrated, and the duration of observation in the studies. As seen in T2DM, there was an increase in the risk of urogenital mycotic infections, but no increase in the risk of severe hypoglycemia. However, concerns arose regarding an increase in incidence of diabetic ketoacidosis. Mitigation strategies, including careful patient selection, extensive education of patients and (para)medical personnel, adequate insulin dose titration, and the adoption of a ketone-centered approach, are suggested. In different areas of the world, SGLTi are approved for use in T1DM with restrictions concerning patient selection and SGLTi dose. Real-world data on the effect of introduction of SGLTi in people with T1DM will yield insight on the robustness of glycemic effects over time, and allow us to determine whether the positive risk–benefit profile observed in clinical trials can be translated to the real world.
has issue date	2020-07-24(xsd:dateTime)
bibo:doi	10.1177/2042018820938545
bibo:pmid	32782777
has license	cc-by-nc
sha1sum (hex)	cf213fb0fd91d61203b8fc221d6102119a67a52b
schema:url	https://doi.org/10.1177/2042018820938545
resource representing a document's title	SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects
has PubMed Central identifier	PMC7383636
has PubMed identifier	32782777
schema:publication	Ther Adv Endocrinol Metab
resource representing a document's body	covid:cf213fb0fd91d61203b8fc221d6102119a67a52b#body_text
is schema:about of	named entity 'glycemic control' named entity 'glucose' named entity 'hypoglycemia' named entity 'T1DM' named entity 'Metabolism' named entity 'type 1 diabetes' named entity 'lipolysis' named entity 'insulin' named entity 'dapagliflozin' named entity 'pregnant women' named entity 'DKA' named entity 'mycotic' named entity 'glucose' named entity 'glucose' named entity 'empagliflozin' named entity 'physical activity' named entity 'dapagliflozin' named entity 'insulin-dependent' named entity 'Ketone' named entity 'ketosis' named entity 'hypoglycemia' named entity 'dehydration' named entity 'DKA' named entity 'infusion set' named entity 'Insulin' named entity 'DKA' named entity 'type 1 diabetes' named entity 'placebo' named entity 'pyrrhic victory' named entity 'glucosuria' named entity 'dapagliflozin' named entity 'T1DM' named entity 'Sentinel program' named entity 'T1DM' named entity 'T1DM' named entity 'DKA' named entity 'mycotic infections' named entity 'sotagliflozin' named entity 'glucosuria' named entity '1.5 million' named entity 'mmHg' named entity 'hypoglycemia' named entity 'phase II study' named entity 'HbA1c' named entity 'insulin' named entity 'glycogen storage disorders' named entity 'ketones' named entity 'DKA' named entity 'SGLT1' named entity 'dapagliflozin' named entity 'canagliflozin' named entity 'significant effect' named entity 'ketone' named entity 'SGLT' named entity 'canagliflozin' named entity 'clinical trials' named entity 'diabetic ketoacidosis' named entity 'hypoglycemia' named entity 'insulin' named entity 'insulin' named entity 'hypoglycemia' named entity 'add-on therapy' named entity 'DKA' named entity 'placebo' named entity 'SGLT' named entity 'glucose levels' named entity '95% CI' named entity 'insulin' named entity 'mycotic' named entity 'clinical presentation' named entity 'hypoglycemia' named entity 'DKA' named entity 'glucose' named entity 'empagliflozin' named entity 'DKA' named entity 'insulin' named entity 'T2DM' named entity 'DKA' named entity 'double-blind'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software